Nicotinamide adenine dinucleotide

Biomarker

5 papers1 finding

Human trial1
Animals1

Interventions

Nicotinamide riboside

upin humans1

1 study

Nicotinamide riboside increases nicotinamide adenine dinucleotide in humans (pre: 23.36 ± 1.94; post: 48.52 ± 4.12 μM vs placebo pre: 24.12 ± 1.70; post: 25.14 ± 1.58 μM).
“Blood NAD + increased with NR (pre: 23.36 ± 1.94; post: 48.52 ± 4.12 μM) compared with placebo (pre: 24.12 ± 1.70; post: 25.14 ± 1.58 μM) with a significant treatment by time interaction ( p <0.001).”
Human trialin older adults with mild cognitive impairmentblood500 mg b.i.d.12 weeksn = 42
A phase‐II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
AAIC 2025 abstract23 Dec 2025

Funding

1 grant since 2025

National Institute on AgingUS$801.4k

Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome
National Institute on AgingBrigham and Women's HospitalUS$801.4k2025–2028

Latest

37 in 12 months

JAMA8 Oct

Nicotinamide riboside did not improve early Parkinson disease

In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.

Randomised trial in 393 peopleNicotinamide riboside

Paper

Frontiers in Nutrition8 Oct